Physician Education: Bridging Clinical Research and Patient Care

IAS-USA Board of Directors Disclosure Information

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

IAS–USA Board of Directors

Constance A. Benson, MD
Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. (Updated 05/22//17)

Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)

Judith S. Currier, MD
Dr Currier has received research grants awarded to her institution from Theratechnologies. (Updated 09/25/17)

Carlos del Rio, MD
Dr del Rio has served as a consultant for InnaVirVax. (Updated 01/17/17)

Roy M. Gulick, MD, MPH
Dr Gulick has no relevant financial affiliations to disclose. (Updated 10/16/17)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 12/6/17)

Jeanne M. Marrazzo, MD, MPH
Dr Marrazzo currently serves on data and safety monitoring board for Gilead Science, Inc. (Updated 08/11/17)

Douglas D. Richman, MD
Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, Merck, and Monogram Biosciences, Inc. (Updated 5/24/17)

Michael S. Saag, MD
Dr Saag has received research grants or has served as a scientific advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, Proteus, and ViiV Healthcare. (Updated 11/29/17)

Robert T. Schooley, MD
Dr Schooley serves as a consultant to CytoDyn and Antiva Biosciences. He is a stockholder of Antiva Biosciences and has stock options from CytoDyn. He serves as a Scientific Advisory Board Member (honoraria remitted to the University of California) for Gilead Sciences, Inc, and LabCorps. (Updated 05/04/17)

Paul A. Volberding, MD
Dr Volberding has served on data and safety monitoring boards for Merck. (Updated 02/24/17)